Literature DB >> 1577257

Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-beta-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366.

S al-Obeid1, D Billot-Klein, J van Heijenoort, E Collatz, L Gutmann.   

Abstract

The mechanism of synergy between vancomycin and penicillin, as well as other beta-lactam antibiotics, was examined in a penicillin-resistant E. faecium (D366) expressing an inducible low-level resistance to vancomycin. It was demonstrated that penicillin per se was not able to reduce the inducible expression of the 39.5-kDa protein (VANB) or the carboxypeptidase activity which are involved in the mechanism of vancomycin resistance of this strain. Assays of competition between 3H-benzylpenicillin and diverse beta-lactam antibiotics suggested as the most likely explanation of the synergy that, once vancomycin resistance has been induced, the high-molecular mass penicillin-binding proteins (PBPs), and possibly PBP1 in particular, which have a high affinity for beta-lactam antibiotics, take over the role of the low-affinity PBP5 which is, in the non-induced strain, responsible for beta-lactam resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577257     DOI: 10.1016/0378-1097(92)90566-7

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  12 in total

Review 1.  Regulation of VanA- and VanB-type glycopeptide resistance in enterococci.

Authors:  M Arthur; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  FemABX peptidyl transferases: a link between branched-chain cell wall peptide formation and beta-lactam resistance in gram-positive cocci.

Authors:  S Rohrer; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Novel mechanism of resistance to glycopeptide antibiotics in Enterococcus faecium.

Authors:  Julie Cremniter; Jean-Luc Mainardi; Nathalie Josseaume; Jean-Charles Quincampoix; Lionel Dubost; Jean-Emmanuel Hugonnet; Arul Marie; Laurent Gutmann; Louis B Rice; Michel Arthur
Journal:  J Biol Chem       Date:  2006-08-29       Impact factor: 5.157

Review 5.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 6.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

7.  Penicillin tolerance and modification of lipoteichoic acid associated with expression of vancomycin resistance in VanB-type Enterococcus faecium D366.

Authors:  L Gutmann; S Al-Obeid; D Billot-Klein; E Ebnet; W Fischer
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

8.  Genetic basis for vancomycin-enhanced cephalosporin susceptibility in vancomycin-resistant enterococci revealed using counterselection with dominant-negative thymidylate synthase.

Authors:  Christopher J Kristich; Dusanka Djorić; Jaime L Little
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

Review 9.  Resistance Mechanisms, Epidemiology, and Approaches to Screening for Vancomycin-Resistant Enterococcus in the Health Care Setting.

Authors:  Matthew L Faron; Nathan A Ledeboer; Blake W Buchan
Journal:  J Clin Microbiol       Date:  2016-05-04       Impact factor: 5.948

10.  Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex.

Authors:  D M Shlaes; J H Shlaes; S Vincent; L Etter; P D Fey; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.